Details of the Drug

General Information of Drug (ID: DMW5ML9)

Drug Name
Tecovirimat
Synonyms Tecovirimat; ST 246; SIGA-246; UNII-F925RR824R; 816458-31-8; F925RR824R; ST-246; TPOXX; Tecovirimat [USAN:INN]; SIGA 246
Indication
Disease Entry ICD 11 Status REF
Smallpox 1E70 Approved [1]
Virus infection 1A24-1D9Z Phase 3 [2]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 376.3
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3-4 h [3]
Clearance
The drug is mainly cleared by the renal [4]
Elimination
Less than 0.02% of the drug is excreted unchanged in the kidney, with a majority of the drug being excreted in glucuronidated form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [5]
Vd
The volume of distribution (Vd) of drug is 1,356 L [4]
Chemical Identifiers
Formula
C19H15F3N2O3
IUPAC Name
N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
Canonical SMILES
C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F
InChI
InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+
InChIKey
CSKDFZIMJXRJGH-VWLPUNTISA-N
Cross-matching ID
PubChem CID
16124688
CAS Number
869572-92-9
DrugBank ID
DB12020
TTD ID
D0MD8D
ACDINA ID
D01467

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Variola virus Envelope phospholipase F13 (VARV p37) TTG7UOF F13_VAR67 Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Erythrosine sodium anhydrous E00324 27872 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Gelatin E00630 Not Available Other agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tecovirimat 200 mg capsule 200 mg Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.IDrugs. 2010 Mar;13(3):181-91. Review
2 ClinicalTrials.gov (NCT02474589) A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat.
3 Grosenbach DW, Jordan R, Hruby DE: Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol. 2011 May;6(5):653-671. doi: 10.2217/fvl.11.27.
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.